Allarity Therapeutics Opens Phase 2 Trial Combining Stenoparib with Temozolomide for Relapsed Small Cell Lung Cancer
核心洞察
Allarity Therapeutics has opened enrollment for a Phase 2 trial combining stenoparib with temozolomide for recurrent small cell lung cancer patients.
The trial is fully funded by the U.S. Department of Veterans Affairs (搜索) and is now enrolling at 11 VA sites across the United States.
Stenoparib's dual PARP/tankyrase inhibition mechanism and favorable safety profile may overcome toxicity limitations seen with first-generation PARP inhibitors.
Allarity Therapeutics has announced the opening of enrollment for a Phase 2 clinical trial evaluating the combination of stenoparib and temozolomide in patients with recurrent small cell lung cancer (SCLC). The trial, conducted in collaboration with the U.S. Department of Veterans Affairs (搜索) (VA), represents the first study combining Allarity's stenoparib with another anti-cancer agent.
The study is fully funded through the VA's Special Emphasis Panel on Precision Oncology and is officially registered as NCT06681220. Enrollment is now open at 11 VA sites throughout the United States, targeting patients with recurrent SCLC who have progressed after frontline treatment.
Novel Dual-Target Approach
Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1 (搜索)/2 and tankyrase 1 (搜索)/2. The drug's unique mechanism addresses two critical pathways in cancer progression: DNA repair through PARP inhibition and the WNT (搜索) signaling pathway through tankyrase inhibition. Aberrant WNT/β-catenin (搜索) signaling has been implicated in the development and progression of numerous cancers, including SCLC.
"Stenoparib has not only a unique mechanism of action that could provide benefit to these patients but also has a favorable safety profile that may allow veterans to tolerate this combination therapy and realize meaningful, durable clinical benefit," said Shadia Jalal, the study's Principal Investigator and Professor of Medicine at the Lawrence H. Einhorn Chair in Oncology at Indiana University's Melvin and Bren Comprehensive Cancer Center.
Addressing Treatment Limitations
The combination strategy addresses a significant clinical challenge in SCLC treatment. Previous clinical work has demonstrated that combining temozolomide with first-generation PARP inhibitors shows activity but has been limited by severe hematologic toxicity. Stenoparib's favorable safety profile, demonstrated in ongoing ovarian cancer trials, may enable better tolerability of the combination regimen.
"Previous clinical work has shown that the combination of temozolomide with first generation PARP inhibitors is very active but also very limited by the toxicities of the two agents," Jalal noted. "Patients with relapsed SCLC including veterans have very few effective treatment options."
Enhanced Therapeutic Potential
Beyond its improved safety profile, stenoparib may offer additional anti-tumor benefits through suppression of WNT (搜索) signaling, a pathway associated with SCLC progression and resistance. The drug's ability to cross the blood-brain barrier presents particular therapeutic potential for patients with brain metastases, a common and challenging complication in advanced SCLC.
Thomas Jensen, Chief Executive Officer of Allarity Therapeutics, emphasized the significance of this development: "Based on clinical data to date from our ongoing trial in ovarian cancer, stenoparib has demonstrated a favorable safety profile, making it a strong candidate for combination therapies — particularly in settings where tolerability has been a limiting factor, as is the case in SCLC."
Biomarker-Directed Treatment
The study incorporates a blood-based biomarker developed in the VA Lung Precision Oncology Program to select patients most likely to benefit from the combination therapy. This approach aligns with Allarity's broader strategy of using its Drug Response Predictor (DRP®) companion diagnostic platform to identify patients with the highest likelihood of treatment benefit.
The DRP® platform builds on comparisons of sensitive versus resistant human cancer cell lines, incorporating transcriptomic information and clinical tumor biology filters. The platform has demonstrated statistically significant prediction of clinical outcomes from drug treatment in cancer patients across dozens of clinical studies.
Expanding Development Program
Allarity has secured exclusive global rights for stenoparib's development and commercialization. The drug was originally developed by Eisai Co. Ltd. (搜索) and was formerly known as E7449 and 2X-121. The company currently has two ongoing Phase 2 trial protocols for stenoparib in ovarian cancer patients, with one protocol designed specifically for platinum-resistant or platinum-ineligible patients to accelerate clinical development toward FDA approval.
The opening of the SCLC combination trial marks an important expansion of stenoparib's clinical development program beyond ovarian cancer, exploring its potential in cancers where the WNT (搜索) signaling pathway plays a key role.